NEWS
-
[August 22, 2022] Chugai and Noile-Immune Biotech Enters into a License Agreement for Noile-Immune’s PRIME CAR-T Technology
-
[December 24, 2021] Start of Phase I clinical trial of NIB103 (TAK-103)
-
[October 25, 2021] Noile-Immune Biotech Enters Collaboration with DAIICHI SANKYO COMPANY, LIMITED on Technology Assessment
-
[September 14, 2021] Announcement of Clinical Trial Notification (CTN) submission of NIB101 Phase 1 Clinical Trial for Solid Tumors in Japan
-
[March 22, 2021] Investment on Noile-Immune Biotech (Series C)
-
[September 14, 2020] Start of Phase I clinical trials of NIB-102 (TAK-102) & Change of NIB’s CEO
-
[June 09, 2020] Noile-Immune Biotech Enters Collaboration with Chugai Pharmaceutical on Technology Assessment
-
[May 25, 2020] Collaboration for allogeneic PRIME CAR-T cell therapy using CRISPR/Cas3 genome editing technology between Noile-Immune Biotech and C4U
-
[May 06, 2020] Collaborative Research and Licensing Agreement between Legend Biotech corporation and Noile-Immune Biotech
-
[March 31, 2020] Strategic partnership via series B financing